Innoviva Total Common and Preferred Stock Dividends Paid 2010-2024 | INVA
Innoviva total common and preferred stock dividends paid from 2010 to 2024. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
Innoviva Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$-70 |
| 2021 |
$-59 |
| 2020 |
$-30 |
| 2019 |
$-11 |
| 2018 |
$-0 |
| 2017 |
$-0 |
| 2016 |
$-1 |
| 2015 |
$-87 |
| 2014 |
$-57 |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.163B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
